Bend Research, part of Capsugel’s Dosage Form Solutions business unit, has added Capsugel’s Xcelodose precision powder-filling technology to its drug development process. This patented micro-dosing technology is intended to enhance Bend’s recently announced Rapid Advancement of Preclinical Compounds initiative. The technology will also facilitate fast and efficient scale up and transfer of powder-fill formulations within Capsugel’s global network of commercial production sites, according to a Bend statement.

“As leaders in bioavailability enhancement and modified release, we are utilizing complementary technologies at Capsugel and Bend Research to improve our collective offerings and help our clients advance their best medicines,” explained Jim Nightingale, president of Bend Research. “For example, integrating Bend Research’s expertise in particle engineering for inhalation, Capsugel’s Xcelodose technology, and Capsugel’s expertise in development of customized dry powder inhalation (DPI) capsules will do just that in the area of inhalation drug development and delivery.”

The Xcelodose 600S precision powder micro-dosing system enables the dispensing of dose weights as low as 100 micrograms, without excipients or bulking agents. Precision capsule fill capability is imperative for dry powder inhalation drug products, said a Bend statement, and the addition of Xcelodose technology to Bend’s drug development technology portfolio will ensures that inhalation drug development can progress from proof of concept through Phase II in 20 weeks or less.